ClinicalTrials.gg
RecruitingNCT07435259Updated Aug 10, 2026

Comparing Implant Retention Versus Removal for MRONJ at Implant Sites

An interventional study of Implant Retention Surgery and Implant Removal Sugery in Medication Related Osteonecrosis of the Jaw, sponsored by Kyunghee University Dental Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Kyunghee University Dental Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Osteoporosis with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis · Korea, Republic of.

Planned enrollment
22nd of 26
50 · median 96
Started
2026
the only one that year
No phase
3 of 39
1 open now
Registered
39th of 39
by date

Among the 39 studies in Osteoporosis with a site in Korea, Republic of, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 39th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

1 of the 39 studies in Osteoporosis with a site in Korea, Republic of is open now.

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Osteoporosis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Medication-related osteonecrosis of the jaw (MRONJ) is a condition that can occur in patients who take medications such as antiresorptive drugs for osteoporosis and other bone-related systemic diseases. Although the overall risk is relatively low, the number of affected patients is increasing as the population ages and dental implants are increasingly used to restore chewing function. When MRONJ develops at an implant site, deciding whether to keep or remove the implant becomes a difficult clinical problem.

Current treatment recommendations for MRONJ are mainly based on disease stage. However, in situations where only part of the bone around an implant is affected, and the entire implant surface is not involved, there are no clear, evidence-based criteria to guide the decision between implant retention and implant removal. Some clinicians recommend removing all implants associated with necrotic bone to reduce the risk of recurrence. Others attempt to preserve implants that appear less severely affected. Implant retention may carry a risk of delayed healing or recurrence, whereas implant removal may cause additional surgical trauma that could potentially worsen the condition. Therefore, more objective criteria are needed to support clinical decision-making.

In peri-implantitis, another disease affecting the tissues around implants, the amount of bone loss observed on radiographs is often used as a reference for treatment decisions. Traditionally, implant removal has been considered when bone loss reaches approximately 50-60% of the implant length. When bone loss is less extensive, treatment aimed at preserving the implant may be attempted. However, it is unknown whether a similar bone loss threshold applies to patients with implant-related MRONJ.

The purpose of this prospective study is to evaluate whether the extent of peri-implant bone loss-particularly within the range of 20% to 60% of the implant length-can serve as a practical reference for deciding whether to retain or remove an implant in patients with implant-related MRONJ. By comparing clinical outcomes between implant retention and implant removal within this range of bone loss, this study aims to determine whether a bone-loss-based criterion can support treatment decisions.

The primary outcome of the study is complete mucosal healing at 6 months after treatment. Additional outcomes, including radiographic changes assessed by cone-beam computed tomography (CBCT) and recurrence of MRONJ-related clinical signs, will also be evaluated during the 1-year follow-up period after treatment initiation. CBCT imaging will be performed at 6 and 12 months after treatment to assess bone changes over time. Approximately 50 patients will be enrolled in this single-center prospective study. The findings are expected to provide structured clinical data to guide implant management decisions in patients with implant-related MRONJ.

Read the detailed description

This is a single-center, prospective study conducted at Kyung Hee University Dental Hospital that compares clinical outcomes between implant retention and implant removal in patients diagnosed with implant-related medication-related osteonecrosis of the jaw (MRONJ).

  1. Background and Rationale:

    Implant-related MRONJ presents a significant clinical challenge in patients receiving antiresorptive therapy. Although both implant retention and implant removal are currently used as treatment strategies, there is insufficient prospective evidence to compare their clinical effectiveness. Most available data are retrospective and heterogeneous. Therefore, a prospective study is needed to generate structured clinical outcomes and to inform future large-scale comparative research.

  2. Study Population:

Eligible participants are adult patients diagnosed with implant-related MRONJ according to established diagnostic criteria. Diagnosis will be based on clinical findings, radiographic evaluation, and the history of the antiresorptive agent. Patients who meet the inclusion criteria and provide informed consent will be prospectively enrolled. Participants with peri-implant MRONJ involving implants with baseline peri-implant bone loss between 20% and 60% on CBCT will be enrolled. Treatment outcomes of implant retention versus removal will be compared to inform decision criteria within this bone-loss range. If multiple implants are involved within a single MRONJ lesion, all affected implants will be included in the analysis.

3) Study Design and Intervention:

  1. Implant Retention Group:

    The affected implant will be preserved, and patients will receive conservative management to control infection, remove necrotic bone as indicated, and promote soft-tissue healing. In the implant retention arm, if intraoperative assessment reveals peri-implant bone loss exceeding 60% of the implant length or compromised implant stability, conversion to implant removal may be performed in accordance with predefined protocol criteria.

  2. Implant Removal Group:

The affected implant will be surgically removed, followed by appropriate debridement and management of the site to promote resolution of necrotic bone and soft-tissue healing.

Treatment allocation will not be randomized. Decisions will be made based on clinical assessment, disease severity, patient preference, and shared decision-making between the patient and the clinician.

4) Outcome Measures:

  1. Primary Outcome:

    The primary endpoint is complete mucosal healing at 6 months after treatment. Complete mucosal healing is defined as full coverage of the previously exposed bone area with intact mucosa and absence of clinical signs of active infection.

  2. Secondary Outcomes:

    • Radiographic marginal bone changes will be assessed using CBCT at 6 and 12 months after treatment. The 6-month CBCT will serve as the reference image after initial healing. Marginal bone changes within approximately 1.0-1.5 mm will be considered physiologic remodeling; greater bone loss will be interpreted as radiographic progression of MRONJ.
    • Recurrence or persistence of MRONJ-related clinical signs and symptoms, including fistula formation, gingival swelling, erythema, suppuration, or exposed bone, during the 1-year follow-up period.

      5) Sample Size and Study Purpose: Approximately 50 patients are expected to be enrolled. As a prospective study, the primary aim is to generate prospective clinical data and evaluate feasibility, clinical trends, and outcome variability. The findings will inform the design and sample size estimation for future larger comparative studies.

      6) Ethical Considerations: This study has been reviewed and approved by the Institutional Review Board of Kyung Hee University Dental Hospital. All participants will provide written informed consent prior to enrollment.

      7) Study Significance: By prospectively comparing implant retention and removal in implant-related MRONJ, this study aims to clarify patterns of clinical outcomes and provide evidence to support decision-making in the management of this complex condition.

03

Conditions studied

  • Medication Related Osteonecrosis of the Jaw

Browse trials for

Keywords

  • Implant-related MRONJ
  • Peri-implant MRONJ
  • Dental implant
  • Peri-implant bone loss
  • Implant retention
  • Implant removal
  • Osteoporosis
  • Antiresorptive therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with medication-related osteonecrosis of the jaw (MRONJ) (AAOMS stage 0, 1, or 2) who have been treated with antiresorptive agents (e.g., bisphosphonates or denosumab) and/or selective estrogen receptor modulators (SERMs).
  • Presence of an MRONJ lesion involving at least one dental implant at the affected site.
  • Radiographic peri-implant bone loss between ≥20% and \<60% of the implant length at the most severe area on baseline imaging.
  • No implant mobility.
  • Able and willing to provide written after receiving an adequate explanation of the study purpose and procedures.

Exclusion criteria

Exclusion Criteria:

  • History of radiotherapy to the head and neck region.
  • Presence of disease or bone diseases such as multiple myeloma or Paget's disease of the jaw.
  • Current treatment with anti-angiogenic agents (e.g., bevacizumab, ranibizumab, lenalidomide, sunitinib) or immunomodulatory agents (e.g., methotrexate) for cancer therapy.
  • Uncontrolled systemic disease that may contraindicate surgery or impair healing (e.g., uncontrolled diabetes, recent chemotherapy, severe ).
  • Refusal of treatment or follow-up, withdrawal of consent, or inability to comply with study procedures.
  • Peri-implant bone loss outside the predefined range (\<20% or ≥60%) on preoperative imaging or intraoperative assessment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Implant Retention

    Participants receive a treatment strategy aimed at preserving the affected implant when feasible. The approach includes surgical management of necrotic bone and decontamination of the exposed implant surface, with the goal of maintaining implant stability and achieving mucosal healing.

    Procedure: Implant Retention Surgery

  • Active comparator
    Implant Removal

    Participants receive a treatment strategy involving surgical removal of the affected implant together with resection of necrotic bone to eliminate the source of infection and promote healing.

    Procedure: Implant Removal Sugery

Interventions

  • ProcedureImplant Retention Surgery

    Surgical removal of necrotic bone surrounding the affected implant is performed. The exposed implant surface is mechanically decontaminated (e.g., using a titanium brush) to reduce biofilm contamination. The surgical site is managed to promote mucosal healing and infection control while preserving implant stability.

  • ProcedureImplant Removal Sugery

    Surgical extraction of the affected implant is performed along with the removal of surrounding necrotic bone. The surgical site is managed to promote mucosal healing and stabilization of the underlying bone.

06

What researchers measure

Primary outcomes

  1. Complete mucosal healing at 6 months after treatment

    Complete resolution of mucosal breakdown with no exposed necrotic bone and no signs of active infection at the treated implant site.

    Time frame: 6 months after surgical treatment

Secondary outcomes

  1. Radiographic stabilization/progression on CBCT

    Radiographic changes in peri-implant bone and surrounding lesion assessed on CBCT to determine stabilization versus progression after treatment, with marginal bone changes within approximately 1.0-1.5 mm considered physiologic remodeling and greater loss interpreted as radiographic progression.

    Time frame: 6 months and 12 months after treatment

  2. Recurrence of MRONJ-related clinical signs

    Recurrence of exposed bone, fistula, infection, or other MRONJ-related clinical signs during follow-up.

    Time frame: Up to 12 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Kyung Hee University Dental Hospital
    Seoul, Seoul 02447, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to the small sample size and the inclusion of imaging data, which may increase the risk of participant re-identification. Data sharing was not included in the IRB-approved protocol.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 11 months is below that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07435259
Lead sponsor
Kyunghee University Dental Hospital
Collaborators
ITI International Team for Implantology, Switzerland
Responsible party
JunhoJung (Associate Professor, Kyunghee University Dental Hospital) — Principal investigator
First posted
Feb 27, 2026
Start date
Apr 6, 2026
Primary completion
Mar 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Junghye Hwang, DDS, MS
Contact
hye867@naver.com
82)10-5166-9154
Junho Jung, DDS, PhD
Contact
ssa204@khu.ac.kr
82)10-9076-9669

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion